Market Overview

Three IPOs Hit Wall Street on February 12

Related EGRX
Eagle Pharmaceuticals Reports Positive Outcomes From Clinical Trial Of Bendamustine HCl Product Delivered Via Low-Volume, Rapidly Infused Admixture
Chimerix, Inc. (CMRX) in Focus: Stock Up 5.6%
3 Attractive Biotech Picks For 2015 (Seeking Alpha)
Related TLMR
Top 4 Small-Cap Stocks In The Money Center Banks Industry With The Highest Profit Margin
10 U.S. Banking Stocks Likely To Benefit From An Expected Interest Rate Increase
Talmer Bancorp: No Thanks, I Like Mine Without The Seasoning (Seeking Alpha)

Since new Federal Reserve Chairman, Janet Yellen, has taken control, the Dow Jones Industrial Average has skyrocketed, and IPOs averaged up about five percent on Wednesday. Investors and traders are looking for more opportunities in the IPO market.

IPOs generally increase as they publicly debut on their respective stock index. Three prominent companies started to publicly trade their index on February 12.

Eagle Pharmaceuticals (NASDAQ: EGRX) is a specialty pharmaceutical that develops and commercializes injectables products. This company is very to other prominent companies in this space. Eagle Pharmaceuticals priced public at $15.00 at 3.35 million shares. In addition, Eagle has granted its respective underwriters an exclusive 30-day option to buy another 502,500 shares of common stock.

Talmer Bancorp (NASDAQ: TLMR) is the holding company for two banks, which operate 94 branches. Talmer opened Wednesday morning at $13.75 after it had originally priced at 15.5 million shares. It priced at 13.00, and luckily for shareholders, Talmer has continued to move higher.

Flexion Therapeutics (NASDAQ: FLXN) shares opened at $16.00 per share, after they had originally priced at $13.00 at five million shares. Like Eagle, Flexion specializes in developing and commercializing injectables pain therapies.

Posted-In: News IPOs


Related Articles (FLXN + EGRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters